Clinical Features and Prognostic Models in Patients with Intrahepatic Cholangiocarcinoma: a Population-Based Analysis

[1]  Jin‐Young Jang,et al.  Comparison of oncologic outcomes of extrahepatic cholangiocarcinoma according to tumor location: perihilar cholangiocarcinoma versus distal bile duct cancer , 2022, Annals of surgical treatment and research.

[2]  W. Ryder,et al.  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial , 2021, The Lancet. Oncology.

[3]  Xin Chen,et al.  Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study , 2021, Scientific Reports.

[4]  Xuehao Wang,et al.  Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study , 2021, Annals of translational medicine.

[5]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[6]  A. Forner,et al.  Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System , 2020, Hepatology.

[7]  Yan Li,et al.  The correlations between socioeconomic status and intrahepatic cholangiocarcinoma in the United States: a population-based study , 2020, Translational cancer research.

[8]  Y. Nakanuma,et al.  The Evaluation of the Eighth Edition of the AJCC/UICC Staging System for Intrahepatic Cholangiocarcinoma: a Proposal of a Modified New Staging System , 2019, Journal of Gastrointestinal Surgery.

[9]  G. Brandi,et al.  Cholangiocarcinoma: Epidemiology and risk factors , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[10]  G. Song,et al.  Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma , 2018, Journal of hepato-biliary-pancreatic sciences.

[11]  G. Gores,et al.  Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.

[12]  T. Pawlik,et al.  Staging of intrahepatic cholangiocarcinoma. , 2017, Hepatobiliary surgery and nutrition.

[13]  M. Mino‐Kenudson,et al.  Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management , 2017, Abdominal Radiology.

[14]  Elijah Dixon,et al.  Epidemiology and risk factors: intrahepatic cholangiocarcinoma. , 2017, Hepatobiliary surgery and nutrition.

[15]  Han Zhang,et al.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. , 2016, Cancer letters.

[16]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[17]  C. Denlinger,et al.  Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma , 2016, Cancer.

[18]  M. Miyazaki,et al.  Intrahepatic cholangiocarcinoma: expert consensus statement. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[19]  P. Kim,et al.  Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. , 2015, Journal of vascular and interventional radiology : JVIR.

[20]  H. Elhalawani,et al.  Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. , 2015, The Cochrane database of systematic reviews.

[21]  R. Plentz,et al.  Clinical presentation, risk factors and staging systems of cholangiocarcinoma. , 2015, Best practice & research. Clinical gastroenterology.

[22]  A. Bergquist,et al.  Epidemiology of cholangiocarcinoma. , 2015, Best practice & research. Clinical gastroenterology.

[23]  Mithat Gonen,et al.  Nomograms in oncology: more than meets the eye. , 2015, The Lancet. Oncology.

[24]  Li Zhang,et al.  Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  X. Pivot,et al.  Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review , 2014, Cancer medicine.

[26]  T. Pawlik,et al.  A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. , 2014, JAMA surgery.

[27]  G. Gores,et al.  Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.

[28]  T. Pawlik,et al.  Staging of intrahepatic cholangiocarcinoma , 2010, Current opinion in gastroenterology.

[29]  S. Taylor-Robinson,et al.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[30]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Thomas,et al.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours. , 2002, Journal of hepatology.

[32]  H. Thomas,et al.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998 , 2001, Gut.

[33]  C. Meyer,et al.  Liver transplantation for cholangiocarcinoma: results in 207 patients. , 2000, Transplantation.

[34]  M. Saadeh,et al.  Liver , 2016, Laboratory Investigation.

[35]  T. Pawlik,et al.  Intrahepatic cholangiocarcinoma: An international, multi-institutional analysis of prognostic factors and lymph node assessment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.